Switch theme
Sign up to access all valuation multiples
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
2015
55
LTM Revenue $0.5M
LTM EBITDA -$60.1M
-$14.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Camp4 Therapeutics has a last 12-month revenue of $0.5M and a last 12-month EBITDA of -$60.1M.
In the most recent fiscal year, Camp4 Therapeutics achieved revenue of $0.7M and an EBITDA of -$51.4M.
Camp4 Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Camp4 Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.3M | $0.7M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$50.2M | -$51.4M | XXX | XXX | XXX |
| EBITDA Margin | -14343% | -7882% | XXX | XXX | XXX |
| Net Profit | -$44.2M | -$49.3M | XXX | XXX | XXX |
| Net Margin | -12626% | -7560% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 28, 2025, Camp4 Therapeutics's stock price is $2.
Camp4 Therapeutics has current market cap of $41.3M, and EV of -$14.1M.
See Camp4 Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$14.1M | $41.3M | XXX | XXX | XXX | XXX | $-8.41 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 28, 2025, Camp4 Therapeutics has market cap of $41.3M and EV of -$14.1M.
Camp4 Therapeutics's trades at -27.4x LTM EV/Revenue multiple, and 0.2x LTM EBITDA.
Analysts estimate Camp4 Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Camp4 Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$14.1M | XXX | XXX | XXX |
| EV/Revenue | -21.6x | XXX | XXX | XXX |
| EV/EBITDA | 0.3x | XXX | XXX | XXX |
| P/E | -0.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCamp4 Therapeutics's NTM/LTM revenue growth is -64%
Camp4 Therapeutics's revenue per employee for the last fiscal year averaged $12K, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Camp4 Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Camp4 Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Camp4 Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 86% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -7882% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -7946% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $12K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2289% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5954% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 8242% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Camp4 Therapeutics acquired XXX companies to date.
Last acquisition by Camp4 Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Camp4 Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Camp4 Therapeutics founded? | Camp4 Therapeutics was founded in 2015. |
| Where is Camp4 Therapeutics headquartered? | Camp4 Therapeutics is headquartered in United States of America. |
| How many employees does Camp4 Therapeutics have? | As of today, Camp4 Therapeutics has 55 employees. |
| Who is the CEO of Camp4 Therapeutics? | Camp4 Therapeutics's CEO is Mr. Joshua Mandel-Brehm. |
| Is Camp4 Therapeutics publicy listed? | Yes, Camp4 Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Camp4 Therapeutics? | Camp4 Therapeutics trades under CAMP ticker. |
| When did Camp4 Therapeutics go public? | Camp4 Therapeutics went public in 2024. |
| Who are competitors of Camp4 Therapeutics? | Similar companies to Camp4 Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Camp4 Therapeutics? | Camp4 Therapeutics's current market cap is $41.3M |
| What is the current revenue of Camp4 Therapeutics? | Camp4 Therapeutics's last 12-month revenue is $0.5M. |
| What is the current EBITDA of Camp4 Therapeutics? | Camp4 Therapeutics's last 12-month EBITDA is -$60.1M. |
| What is the current EV/Revenue multiple of Camp4 Therapeutics? | Current revenue multiple of Camp4 Therapeutics is -27.4x. |
| What is the current EV/EBITDA multiple of Camp4 Therapeutics? | Current EBITDA multiple of Camp4 Therapeutics is 0.2x. |
| What is the current revenue growth of Camp4 Therapeutics? | Camp4 Therapeutics revenue growth between 2023 and 2024 was 86%. |
| Is Camp4 Therapeutics profitable? | Yes, Camp4 Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
